SEOUL - South Korea has to quickly begin reimbursement of immuno-oncology drugs even if it is just for certain limited patient populations, in order to improve patients’ access and ease their financial burden, experts say.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?